Cargando…

Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer

Whether neoadjuvant therapy confers a survival benefit in advanced prostate cancer (PCa) remains uncertain. The primary endpoints of previous retrospective and phase II clinical studies that used neoadjuvant therapy, including androgen deprivation therapy combined with new-generation androgen recept...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Yongbao, Zhang, Ruochen, Zhong, Dewen, Chen, Zhensheng, Chen, Gen, Yang, Minggen, Lin, Le, Li, Tao, Ye, Liefu, Chen, Lili, Zhu, Qingguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620516/
https://www.ncbi.nlm.nih.gov/pubmed/37927597
http://dx.doi.org/10.3389/fphar.2023.1284899
_version_ 1785130223681929216
author Wei, Yongbao
Zhang, Ruochen
Zhong, Dewen
Chen, Zhensheng
Chen, Gen
Yang, Minggen
Lin, Le
Li, Tao
Ye, Liefu
Chen, Lili
Zhu, Qingguo
author_facet Wei, Yongbao
Zhang, Ruochen
Zhong, Dewen
Chen, Zhensheng
Chen, Gen
Yang, Minggen
Lin, Le
Li, Tao
Ye, Liefu
Chen, Lili
Zhu, Qingguo
author_sort Wei, Yongbao
collection PubMed
description Whether neoadjuvant therapy confers a survival benefit in advanced prostate cancer (PCa) remains uncertain. The primary endpoints of previous retrospective and phase II clinical studies that used neoadjuvant therapy, including androgen deprivation therapy combined with new-generation androgen receptor signaling inhibitors or chemotherapy, were pathological downstaging, progression-free survival, prostate-specific antigen relief, and local symptom improvement. To the best of our knowledge, no studies have explored the efficacy and safety of neoadjuvant therapy in improving the surgical resection rate in cases of unresectable primary tumors of PCa. We first designed this retrospective study to evaluate the potential value of apalutamide as neoadjuvant therapy in improving the resectability rate of radical prostatectomy (RP). We initially reported 7 patients with unresectable primary lesions who underwent neoadjuvant apalutamide treatment for a median of 4 months, and all of them successfully underwent RP treatment. Our study supported apalutamide as neoadjuvant therapy, which helped improve RP’s success rate and did not significantly increase perioperative complications, and the neoadjuvant therapy was controllable. Our findings’ clinical value and benefit for survival still need further clinical research to confirm.
format Online
Article
Text
id pubmed-10620516
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106205162023-11-03 Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer Wei, Yongbao Zhang, Ruochen Zhong, Dewen Chen, Zhensheng Chen, Gen Yang, Minggen Lin, Le Li, Tao Ye, Liefu Chen, Lili Zhu, Qingguo Front Pharmacol Pharmacology Whether neoadjuvant therapy confers a survival benefit in advanced prostate cancer (PCa) remains uncertain. The primary endpoints of previous retrospective and phase II clinical studies that used neoadjuvant therapy, including androgen deprivation therapy combined with new-generation androgen receptor signaling inhibitors or chemotherapy, were pathological downstaging, progression-free survival, prostate-specific antigen relief, and local symptom improvement. To the best of our knowledge, no studies have explored the efficacy and safety of neoadjuvant therapy in improving the surgical resection rate in cases of unresectable primary tumors of PCa. We first designed this retrospective study to evaluate the potential value of apalutamide as neoadjuvant therapy in improving the resectability rate of radical prostatectomy (RP). We initially reported 7 patients with unresectable primary lesions who underwent neoadjuvant apalutamide treatment for a median of 4 months, and all of them successfully underwent RP treatment. Our study supported apalutamide as neoadjuvant therapy, which helped improve RP’s success rate and did not significantly increase perioperative complications, and the neoadjuvant therapy was controllable. Our findings’ clinical value and benefit for survival still need further clinical research to confirm. Frontiers Media S.A. 2023-10-19 /pmc/articles/PMC10620516/ /pubmed/37927597 http://dx.doi.org/10.3389/fphar.2023.1284899 Text en Copyright © 2023 Wei, Zhang, Zhong, Chen, Chen, Yang, Lin, Li, Ye, Chen and Zhu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wei, Yongbao
Zhang, Ruochen
Zhong, Dewen
Chen, Zhensheng
Chen, Gen
Yang, Minggen
Lin, Le
Li, Tao
Ye, Liefu
Chen, Lili
Zhu, Qingguo
Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
title Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
title_full Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
title_fullStr Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
title_full_unstemmed Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
title_short Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
title_sort androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620516/
https://www.ncbi.nlm.nih.gov/pubmed/37927597
http://dx.doi.org/10.3389/fphar.2023.1284899
work_keys_str_mv AT weiyongbao androgendeprivationtherapyplusapalutamideasneoadjuvanttherapypriorradicalprostatectomyforpatientswithunresectableprostatecancer
AT zhangruochen androgendeprivationtherapyplusapalutamideasneoadjuvanttherapypriorradicalprostatectomyforpatientswithunresectableprostatecancer
AT zhongdewen androgendeprivationtherapyplusapalutamideasneoadjuvanttherapypriorradicalprostatectomyforpatientswithunresectableprostatecancer
AT chenzhensheng androgendeprivationtherapyplusapalutamideasneoadjuvanttherapypriorradicalprostatectomyforpatientswithunresectableprostatecancer
AT chengen androgendeprivationtherapyplusapalutamideasneoadjuvanttherapypriorradicalprostatectomyforpatientswithunresectableprostatecancer
AT yangminggen androgendeprivationtherapyplusapalutamideasneoadjuvanttherapypriorradicalprostatectomyforpatientswithunresectableprostatecancer
AT linle androgendeprivationtherapyplusapalutamideasneoadjuvanttherapypriorradicalprostatectomyforpatientswithunresectableprostatecancer
AT litao androgendeprivationtherapyplusapalutamideasneoadjuvanttherapypriorradicalprostatectomyforpatientswithunresectableprostatecancer
AT yeliefu androgendeprivationtherapyplusapalutamideasneoadjuvanttherapypriorradicalprostatectomyforpatientswithunresectableprostatecancer
AT chenlili androgendeprivationtherapyplusapalutamideasneoadjuvanttherapypriorradicalprostatectomyforpatientswithunresectableprostatecancer
AT zhuqingguo androgendeprivationtherapyplusapalutamideasneoadjuvanttherapypriorradicalprostatectomyforpatientswithunresectableprostatecancer